STUDI PENGGUNAAN OBAT DISLIPIDEMIA PADA PASIEN SINDROMA NEFROTIK (Penelitian di Instalasi Rawat Jalan Poliklinik Ginjal dan Hipertensi RSUD Dr. Soetomo Surabaya)

KHOLIS NUR AINIAH, 050911163 (2013) STUDI PENGGUNAAN OBAT DISLIPIDEMIA PADA PASIEN SINDROMA NEFROTIK (Penelitian di Instalasi Rawat Jalan Poliklinik Ginjal dan Hipertensi RSUD Dr. Soetomo Surabaya). Skripsi thesis, UNIVERSITAS AIRLANGGA.

[img]
Preview
Text (ABSTRAK)
gdlhub-gdl-s1-2014-ainiahkhol-29562-7.abstr-t.pdf

Download (133kB) | Preview
[img] Text (FULLTEXT)
gdlhub-gdl-s1-2014-ainiahkhol-29562-1.FULLTEXT.pdf
Restricted to Registered users only

Download (1MB) | Request a copy
Official URL: http://lib.unair.ac.id

Abstract

Nephrotic Syndrome (NS) is one of the renal diseases was characterized by proteinuria greater than 3.5 g/day per 1.73 m2, hypoproteinemia (hypoalbuminemia), edema, dyslipidemia. Most of NS was caused by glomerular immune complex reaction that increase glomerular permeability which result in proteinuria. Then, Hypoalbuminemia due to proteinuria would cause increase of albumin synthesis in the liver and was followed by lipoproteins synthesis in the liver that can cause dyslipidemia. Dyslipidemia in NS is a high risk for cardiovascular disease, atherosclerosis, and progressive glomerular damage. Therefore, the optimal lipid lowering drug therapy was required for control lipid levels of patients. The aim of this study is to identify and evaluate the use of lipid lowering drugs on patients with NS, particularly on the dose and drug related problems at the Nephrology and Hypertension Outpatient Department Dr. Soetomo General Hospital Surabaya from December 2012 to Mei 2013. The data was collected using cross-sectional method and analyzed descriptively. The result of this study show that 60% of the patients have very high LDL cholesterol, 73.3% patients with high of total cholesterol, 53.4% patients with high of triglyceride, and 26.6% patients with low of HDL cholesterol. All of 15 patients with NS received simvastatin and the most prescribed dose was 20 mg daily in the evening. Plasma lipid targets based on NCEP ATP III were achieved by 28.6% of 7 patients after more than 6 weeks treatment. The drug related problems were founded in this study was the low patient’s compliance.

Item Type: Thesis (Skripsi)
Additional Information: KKB KK-2 FF.FK 55/13 Ain s
Uncontrolled Keywords: Drug Utilization Study
Subjects: R Medicine > RS Pharmacy and materia medica > RS1-441 Pharmacy and materia medica
Divisions: 05. Fakultas Farmasi > Farmasi Klinis
Creators:
CreatorsNIM/NIDN
KHOLIS NUR AINIAH, 050911163UNSPECIFIED
Contributors:
ContributionNameNIDN/NIDK/NUP
ContributorDr. Budi Suprapti, Apt., M.Si, Dr., Apt., M.SiUNSPECIFIED
Depositing User: shiefti dyah alyusi
Date Deposited: 21 Jan 2014 12:00
Last Modified: 12 Aug 2016 06:41
URI: http://repository.unair.ac.id/id/eprint/9778
Sosial Share:

Actions (login required)

View Item View Item